


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
+9.34%
+1.63%
-8.67%
+20.62%
-7.12%
BNTX
BioNTech
$104.85
Strengths

Earnings are forecast to grow
Chart
$102.25 (+2.54%)
$113.52 (-7.64%)
$104.4 (+0.43%)
$108.23 (-3.12%)
BNTX has Moderate risk level based on volatility, sector strength, volume, investor confidence, and outlook.
Click here to check what is your level of risk
Risks Indicators

Beta greater than 1.0

BNTX overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Below analyst estimate
Rating
Rating
Momentum
Momentum

Price value has negative momentum
Activity
Activity
Future
Future

Earnings are forecast to grow
![]()
BNTX Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
BNTX Street Sentiment is unimpressive and have negative views on the near-term outlook
Average key support and resistance price levels.
Login to displayWhat is BNTX current stock price?
What are BNTX stock strengths?
What risks are associated with BNTX stock?
When is BNTX next earnings report?
What is BNTX market cap and volume?
What is BNTX's current Stock IQ?
Should I buy BNTX stock right now?
Is BNTX a Strong Buy right now?
What does a 'Strong Buy' rating mean for BNTX?
What does a 'Strong Sell' rating mean for BNTX?
What factors influence BNTX's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+9.34%
+1.63%
-8.67%
+20.62%
-7.12%
BNTX
BioNTech
Current Price
$104.85
Stock Insights
Strengths

Earnings are forecast to grow

Chart
$102.25 (+2.54%)
$113.52 (-7.64%)
$104.4 (+0.43%)
$108.23 (-3.12%)
BNTX Analysts Opinion
BNTX Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Below analyst estimate
Rating
Rating
Momentum
Momentum

Price value has negative momentum
Activity
Activity
Future
Future

Earnings are forecast to grow
![]()
BNTX Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
BNTX Street Sentiment is unimpressive and have negative views on the near-term outlook
BNTX has Moderate risk level based on volatility, sector strength, volume, investor confidence, and outlook.
Click here to check what is your level of risk
Risks Indicators

Beta greater than 1.0

Average key support and resistance price levels.
BNTX Latest Analysis
UBS Maintains BioNTech SE - Depositary Receipt (BNTX) Neutral Recommendation. Fintel reports that on November 6 2025 UBS maintained coverage of BioNTech SE - Depositary Receipt (NasdaqGS:BNTX) with a Neutral recommendation. Analyst Price Forecast Suggests 33.63% Upside
Fri Nov 7, 2025
BioNTech SE (NASDAQ:BNTX) Q3 2025 Earnings Call Transcript. BioNTech SE (NASDAQ:BNTX) Q3 2025 Earnings Call Transcript November 3 2025 BioNTech SE misses on earnings expectations. Reported EPS is $-0.14 EPS expectations were $0.75. Operator: Welcome to BioNTech’.s Third Quarter 2025 Earnings Call. I will now hand the call over to Doug Maffei Vice President Strategy and Investor Relations. Please go ahead. Douglas Maffei: [….]
Tue Nov 4, 2025
BioNTech Sees Higher 2025 Sales Driven By Bristol Myers Partnership. ) reported a third-quarter per-share loss of 14 cents (12 cents in euros) on Monday a turnaround from earnings of 81 cents reported a year ago missing the consensus .BNTX shares are consolidating after recent moves. The COVID-19 vaccine maker $1.78 billion (1.52 billion euros) compared to 1.24 billion euros a year ago beatingthe consensus of $1.19 billion.The increase was primarily driven by revenues related to BioNTech’.
Mon Nov 3, 2025
JP Morgan Maintains BioNTech SE - Depositary Receipt (BNTX) Neutral Recommendation. Fintel reports that on October 23 2025 JP Morgan maintained coverage of BioNTech SE - Depositary Receipt (NasdaqGS:BNTX) with a Neutral recommendation. Analyst Price Forecast Suggests 32.96% Upside
Fri Oct 24, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
BNTX Stock trends
BNTX Stock performance
BNTX Stock analysis
BNTX investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.